Category Archives: Biotechnology

Dr. Felister Makini, Deputy Director General (crops) at the Kenya Agricultural & Livestock Research Organization (KALRO), noted that African women play a critical role in ensuring food security. She urged the government to make farming easier for them by providing modern tools such as biotechnology. As African women, we are the ones who suffer most whenever drought and food shortages strike, despite the availability of technological solutions to these problems, she said. We need to speak with one voice and advocate for a predictable policy environment. I have children and a family to protect. I cannot advocate for something that I know would affect them she added. On her part, Prof. Caroline Thoruwa, Chairperson, African Women in Science and Engineering (AWSE), noted that for Africa to advance in agri-biotech, women must be involved. It is time to tell the public about the positive side of biotechnology. We need to raise up the status of women in biotechnology and also encourage women to network in order to achieve the noble goal of sharing their science, she said. The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:AFRICAN WOMEN IN BIOSCIENCES CALL … Continue reading →

Barron's Alerus Financial NA Has $7.606 Million Stake in iShares NASDAQ Biotechnology Index (IBB) The Cerbat Gem iShares NASDAQ Biotechnology Index logo Alerus Financial NA boosted its position in iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 0.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange ... iShares NASDAQ Biotechnology Index (IBB) Stake Increased by Vigilant Capital Management LLCMarkets Daily iShares NASDAQ Biotechnology Index (IBB) Stake Maintained by Cullen Frost Bankers Inc.Sports Perspectives This Biotech ETF Has 'Bullish Potential' - Barron'sBarron's Chaffey Breeze -BBNS -Petro Global News 24 all 10 news articles » Read more from the original source: Alerus Financial NA Has $7.606 Million Stake in iShares NASDAQ Biotechnology Index (IBB) - The Cerbat Gem … Continue reading →

Cellect Biotechnology Ltd, based in Israel, has developed an innovative technology which enables the production of stem cells to therapies and treatments that require stem cells as the main raw material. The company trades on both the Tel Aviv Stock Exchange (TASE) and NASDAQ, and had a market capitalisation at TASE of ca. 45 million USD (prior to the release of Frost & Sullivan report today). Frost & Sullivan publishes equity research reports on technology, biomed and healthcare companies that are listed on the TASE, within the framework of the analysis program that the TASE has initiated. Key goals of the program are enhancing global awareness of these companies and enabling more informed investment decisions by investors interested in hot Israeli hi-tech and healthcare companies. In the coming months, Frost & Sullivan will release 9 additional initiation coverage reports, covering the other companies that have joined the programme: 6 biomed companies Aposense, Brainsway, BiolineRX, Kitov Pharmaceuticals, D.N.A. Biomedical Solutions, and Redhill Biopharma; and 3 technology companies: Safe-T Group, Vonetize and Energix Renewable Energies. For the purpose of equity research services, Frost & Sullivan, the leading global consulting, and market research firm, will leverage relevant analysts, experts and growth consultiants among … Continue reading →

Advances in science, many of them from scientists at USDA or through research funded by USDA, have opened up new options for farmers responding to market needs and environmental challenges. Many new plant varieties being developed or grown by farmers have been produced using genetic engineering, which involves manipulating the plant's genes through techniques of modern molecular biology often referred to as recombinant DNA technology. These techniques are included in what is often referred to as "biotechnology" or "modern biotechnology." USDA supports the safe and appropriate use of science and technology, including biotechnology, to help meet agricultural challenges and consumer needs of the 21st century. USDA plays a key role in assuring that biotechnology plants and products derived from these plants are safe to be grown and used in the United States. Once these plants and products enter commerce, USDA supports bringing these and other products to the worldwide marketplace. Three federal agencies are involved in ensuring that plants produced using biotechnology and the many products derived from them are safe for farmers to use, safe to consume as food or feed, and safe for the environment. These are USDA's Animal and Plant Health Inspection Service, the Department of Health … Continue reading →

Monday, May 1, 2017 11:31 AM UTC Dublin, May 01, 2017 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Animal Biotechnology - Technologies, Markets and Companies" to their offering. This report describes and evaluates animal biotechnology and its application in veterinary medicine and pharmaceuticals as well as improvement in food production. Knowledge of animal genetics is important in the application of biotechnology to manage genetic disorders and improve animal breeding. Genomics, proteomics and bioinformatics are also being applied to animal biotechnology. Transgenic technologies are used for improving milk production and the meat in farm animals as well as for creating models of human diseases. Transgenic animals are used for the production of proteins for human medical use. Biotechnology is applied to facilitate xenotransplantation from animals to humans. Genetic engineering is done in farm animals and nuclear transfer technology has become an important and preferred method for cloning animals.There is discussion of in vitro meat production by culture Biotechnology has potential applications in the management of several animal diseases such as foot-and-mouth disease, classical swine fever, avian flu and bovine spongiform encephalopathy. The most important biotechnology-based products consist of vaccines, particularly genetically engineered or DNA vaccines. … Continue reading →

TORONTO , May 1, 2017 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, will be exhibiting at the American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference in San Diego , California. "We are pleased to be a contributor to this very prestigious conference," said Andrew Morris , CEO of SQI Diagnostics. "This event brings together the world's leading experts and representatives from all sectors of pharma and biotechnology drug development and gives us the opportunity to share our novel multiplexing applications in drug development testing. Over the past year, we have made significant progress in our work with our pharma and biotech customers and believeour unique productswill prove to be beneficial to our customers who are large, global pharmaceutical companies. The conference will run from May 1-3 , 2017. Please stop by and visit us at booth 316. About SQI Diagnostics SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company's proprietary microarray tests and fully-automated systems are designed to simplify protein and … Continue reading →

Is stories Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) Soars On Xenetic Biosciences Inc. (NASDAQ:XBIO) Distribution ... StockNewsUnion Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) continues to power high in the market on the back of a recently announced product distribution deal. A deal with Xenetic Biosciences is expected to make the company's products available on the ... Quarterly EPS analysis of Prana Biotechnology Ltd (NASDAQ:PRAN)The Newburgh Press Buzzer to Observe: Prana Biotechnology Limited's (PRAN)Is stories Eye Catching Stocks Huntsman Corporation (NYSE:HUN), Prana Biotechnology Limited (ADR) (NASDAQ:PRAN)Daily News Journal all 7 news articles » View original post here: Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) Soars On Xenetic Biosciences Inc. (NASDAQ:XBIO) Distribution ... - StockNewsUnion … Continue reading →

USA Commerce Daily Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of ... The Cerbat Gem Puma Biotechnology logo Equities analysts expect that Puma Biotechnology Inc (NYSE:PBYI) will announce earnings per share (EPS) of ($2.08) for the current ... Should You Buy, Sell, Or Hold? Puma Biotechnology, Inc. (PBYI ...USA Commerce Daily Stock Jumping Abnormally High: Puma Biotechnology, Inc. (PBYI)HugoPress Focusing the Lens on Puma Biotechnology, Inc. (NASDAQ:PBYI ...Rives Journal Midway Monitor -Concord Register all 9 news articles » More here: Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of ... - The Cerbat Gem … Continue reading →

Puma Biotechnology, Inc. (PBYI) Credit Suisse Maintains Puma Biotechnology, Inc. (PBYI)s stock to Outperform with the price target of $111. This rating was issued on 9/22/16. The stock recently closed its previous session at $37.25 by showing a percentage change of 1.09% from its previous day closing price of $36.85. Price Target is basically a projection of future price of a companys stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock. Several investment firms issued their expert ratings on Puma Biotechnology, Inc. (PBYI) in which Stifel Nicolaus Upgrades Puma Biotechnology, Inc. (PBYI) to Buy with no specific Price Target on 9/21/16. UBS Maintains the stock to Buy on 4/11/16 by stationing a price target of $60. JP Morgan Maintains the companys stock to Overweight on 3/29/16 by setting a price target of $89. RBC Capital Downgrades Puma Biotechnology, Inc. (PBYI) to Sector Perform with a price target of $36. Puma Biotechnology, Inc. (PBYI) currently has a consensus Price Target of $68.67. While some analysts have a High Price target for the stock … Continue reading →

By Isabella Zhong Shenyang-based 3SBio (1530.HK) is a biopharmaceutical pioneer that offers a unique play on Chinas rising demand for healthcare. The company is best known for its rheumatoid arthritis drug YSP, which accounts for 33% of revenues, and TPIAO, a hormone used in the treatment of platelet deficiencies. While YSP and TPIAO are expected to deliver strong sales growth in coming years, a recent price cut for anemia drug EPIAO and limited R&D upside in the near term could weigh on 3SBio. Jefferies analyst Eugene Huang initiated coverage of the stock today with a hold rating and an HKD11.50 a share target price, which implies 11% upside. Huang has more on 3SBios drugs pipeline: 3SBios HER2 (breast cancer) and CD20 (lymphoma) candidates were withdrawn, leaving peers like Fosun potentially to become FTM generics. Besides, we factored in Rmb20/50/110m 17/18/19E sales from Bydureon (exenatide ER, GLP-1, diabetes), which is pending NDA approval. We are concerned there might be a lack of synergy between 3SBio and AstraZenecas diabetes team as well as integration risks. Shares of 3SBio are up 37% this year and trade at 23 times forward earnings, which is in line with its five year average. Analysts surveyed by … Continue reading →